Vera Therapeutics Q3 Loss Narrower Than Expected at $93.7M
VERA sits 34% above its 52-week low of $23.05.
Summary
Vera Therapeutics posted a Q3 net loss of $93.711 million, well narrower than the IBES estimate of -$117.1 million, and reported $10.3 million in Q3 product revenue. Operating loss came in at $95.702 million versus the -$119 million consensus, with operating expenses of $105.979 million. The beat follows the September ORIGIN 3 final efficacy readout, where TRUTAKNA met all prespecified endpoints, and comes as the company spends heavily to prepare for commercial launch. In late October the company drew $75 million under its debt facility, bringing pro forma cash and marketable securities to $459 million, with up to $350 million still available. The narrower-than-expected loss shows spending discipline relative to expectations while the launch build-out continues.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Vera drew $75 million under its debt facility in late October, bringing pro forma cash and marketable securities to $459 million, with up to $350 million still available.
At the time of this announcement, VERA was trading at $30.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $23.05 to $56.05. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.